Pharmaceutical News

RSS

FDA approves Galderma's Mirvaso topical gel for facial erythema of rosacea

Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.

27 Aug 2013

BARDA Awards Novan $7.8M To Develop Thermal Burns Treatment

...

26 Aug 2013

FDA grants marketing approval for VALCHLOR gel for treatment of early stage CTCL

Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for the orphan drug VALCHLOR (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.

26 Aug 2013

Scientists receive NIH grant to study commercially-available drug for treatment of PMS

Scientists at the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai have received a grant from the National Institutes of Health (NIH) to study Insulin-Like Growth Factor-1 (IGF-1), a promising treatment for a subtype of autism called Phelan McDermid Syndrome (PMS).

26 Aug 2013

CeBiTec researchers successfully sequence genome of Chinese hamster

Genome researchers from Bielefeld University's Center for Biotechnology (CeBiTec) headed by Professor Dr. Alfred P-hler have succeeded in sequencing the genome of the Chinese hamster. The Chinese hamster supplies the cell cultures used by the pharmaceutical industry to produce biopharmaceutical products such as antibodies used in medicine.

26 Aug 2013

Researchers discover link between epilepsy drug and risk of having baby with birth defects

In a world first, new Australian medical research has given pregnant women with epilepsy new hope of reducing their chance of having a baby with physical birth defects.

26 Aug 2013

Athera Transfers Annexin A5 Project To Medirista

...

23 Aug 2013

Shire Renews Rare Genetic Disease Collab With Santaris

...

23 Aug 2013

Athera Transfers Annexin A5 Project To Medirista

...

23 Aug 2013

Shire Renews Rare Genetic Disease Collab With Santaris

...

23 Aug 2013

Early antiretroviral therapy treatment benefits HIV-infected infants

Giving antiretroviral therapy immediately after diagnosis for a limited period of time is more beneficial than postponing treatment in young infants infected with HIV, slowing progression of the disease and delaying the time to starting long-term ART, according to new research published in The Lancet.

23 Aug 2013

Report shows nonmedical use of pain relievers may increase risk of using heroin later

A new report by the Substance Abuse and Mental Health Services Administration (SAMHSA) shows that people aged 12 to 49 who had used prescription pain relievers nonmedically were 19 times more likely to have initiated heroin use recently (within the past 12 months of being interviewed) than others in that age group (0.39 percent versus 0.02 percent).

23 Aug 2013

Moffitt Cancer Center study could offer hope to melanoma sufferers

A new study at Moffitt Cancer Center could offer hope to people with melanoma, the deadliest form of skin cancer. Researchers are investigating whether an injectable known as PV-10 can shrink tumors and reduce the spread of cancer.

23 Aug 2013

Drug to treat blood cancers may also stop spread of invasive breast cancer

A drug used to treat blood cancers may also stop the spread of invasive breast cancer, researchers at Mayo Clinic in Florida have discovered. Their study, published online in Breast Cancer Research, found that in the lab and in animals, the drug decitabine turns on a gene coding for protein kinase D1 (PRKD1) that halts the ability of cancer cells to separate from a tumor and spread to distant organs.

23 Aug 2013

Mount Sinai, Exosome Partner On Body Fluid Molecular Diagnostics

...

22 Aug 2013

Evotec And Jain Extend Research Collab In Skeletal Muscular Dystrophy

...

22 Aug 2013

Adimab Scores Two Deals And Some Milestone Payments

...

22 Aug 2013

New Pharmacological Drug Target Identified In The Brain

...

22 Aug 2013

Nuvo: FDA accepts to review New Drug Application for PENNSAID 2%

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that its U.S. licensee for PENNSAID (diclofenac sodium topical solution) 1.5% w/w and PENNSAID 2% (diclofenac sodium topical solution) 2% w/w, Mallinckrodt has advised that the U.S. Food and Drug Administration has accepted for filing and review the New Drug Application for PENNSAID 2% submitted by Mallinckrodt on August 7, 2013.

22 Aug 2013

Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

Novartis announced today that it has begun shipment of its seasonal influenza vaccines to customers in the US market for the 2013-2014 season. Novartis plans to ship a minimum of 30 million doses of its influenza vaccines to the US market, including Fluvirin (Influenza Virus Vaccine), approved for use in people 4 years of age and older, and Flucelvax (Influenza Virus Vaccine), approved for use in adults 18 years of age and older.

22 Aug 2013